Further correlation analysis between the Tumor Immune Dysfunction and Exclusion (TIDE) score and the Immune Prognostic Score (IPS) suggests a compelling association with CHSY3 expression, thereby impairing the efficacy of immune-based therapies. Here, CHSY3 is linked to neoplasm.